To my mind it is unambiguously positive. Firstly, they are now dealing with the Neurology department, secondly they have basically submitted what the EMA has approved and said does this work for you ?.
If there was some guidance to give or some areas of concerns from the FDA you would get an in person meeting where they could speak more off the record or provide the required nudges to approch. So to my mind that means the FDA see things as being pretty straightforward at this stage. So I suspect they are either "yes, broadly this works for us" or "No, this does not work for us at all". I strongly lean to the former, while from time to time there can be differences of approach between the EMA and FDA, they tend to see things the same way far more than they seem them differently.
- Forums
- ASX - By Stock
- IXC
- Ann: Invex Granted Type C Meeting with FDA
IXC
invex therapeutics ltd
Add to My Watchlist
0.00%
!
9.1¢

Ann: Invex Granted Type C Meeting with FDA, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.839M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 41290 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 9000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 41290 | 0.088 |
1 | 42086 | 0.083 |
1 | 40000 | 0.075 |
1 | 14285 | 0.070 |
1 | 16666 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 9000 | 1 |
0.099 | 59180 | 2 |
0.105 | 50000 | 1 |
0.150 | 713 | 1 |
0.000 | 0 | 0 |
Last trade - 16.21pm 04/07/2025 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online